Topic Listing for Compugen

Accounts Auditors Adds Additional Diagnostic Areas
Agreement Includes Research Collaboration Worldwide License Option Teva Agreement Provides Bayer Schering Pharma Option Worldwide Exclusive
Alex Kotzer Assumes President Ceo Position Alternate Directors
Annual Extraordinary General Meetings Annual General Meeting Shareholders Held Tuesday 2005
Annual General Meeting Shareholders Held Wednesday 2006 Annual Special General Meetings
Anti-takeover Provisions Israeli Law Appoint Kost Forer Gabbay Kasierer Member Ernst Young
Approach Biotechnological Research Approach Discovering Novel Therapeutic Diagnostic Product Candidates Itself
Approach Research Discovery Approval Amendment Articles Association
Approval Certain Compensation Chief Executive Officer Director Approval Certain Transactions
Approval Compensation Officers Approval Compensation Terms Non-management Directors
Approval Directors Officer Letter Indemnification Approval Extension Exercisability Certain Vested Options Granted Alex
Approval Extension Term Non-management Directors Exercise Vested Options Approval Issuance Options Chairman Board Directors
Approval Issuance Options Co-chief Executive Officer Director Approval Issuance Shares Options Well Change Employement Agreement
Approval Stock Option Issuance Chairman Board Approvals Required Compensation Directors
Approximately Received 1000000 Evogene Shares Asset Purchase Agreement
Asset Purchase Agreement Loan Keddem Bioscience Ltd Audit Committee
Audit Committee Financial Expert Background
Base Budget Operating Expenses Cash Flow Bi-national Industrial Research Development Foundation Bird
Bioaccelerator Business Bioaccelerator Business Cont
Biological Efficacy Demonstrated Drug Candidates Pilot Run Biomarker Discovered Using Compugens Geneva Platform
Biosite Agreement Includes Research Collaboration Worldwide License Option Biosite Incorporated
Biotechnology Pharmaceutical Industries Highly Competitive Unable Compete Effectively Board Directors Audit Committee Present Following Ordinary Resolution
Board Directors Present Following Resolution Meeting Board Directors Recommends Shareholders Vote Approval Undertaking Indemnify
Business Difficult Evaluate Because Limited History Operations Operate Business Overview
Cad Stroke Cannot Provide Assurance Business Model Succeed Generating Revenues
Cantor Fitzgerald Capital Gains Tax Sale Ordinary Shares Residents Non-residents
Capital Gains Tax Sale Publicly Traded Ordinary Shares Cardio-vascular Indications
Cash Equivalents Cautionary Statement Regarding Forward-looking Statements
Cautionary Statements Certification Pursuant 302 Sarbanes-oxley Act 2002
Certification Pursuant 906 Sarbanes-oxley Act 2002 Cgen 855 Targets Fprl1 G-protein Coupled Receptor
Cgen-25007 Was Predicted Using Compugens Dac Blockers Discovery Cgen-25017 Peptide Was Predicted Using Compugens Dac Blockers
Cgen-34 Splice Variant Anp Atrial Natriuretic Peptide Hormone Challenges Converting Genomic Data Useful Information
Changes Internal Control Over Financial Reporting Chief Executive Officer
Clinical Development Marketing Products Based Discoveries Subject Governmental Code Ethics
Collaboration Based Compugen Discovered Vegf Receptor Splice Variant Collaboration Based Compugens Geneva Platform
Collaborators Unable Obtain Regulatory Approval Therapeutic Diagnostic Candidates Commercializing In-house Discoveries
Commitments Contingencies Compensation
Compensation Expenses Attributed Option Grants Competition
Compugen Compugen 2008 Conference Call Held 1000 Edt Wednesday
Compugen Announces Additional Grants Israel Office Chief Scientist Compugen Announces Discovery Novel Drug Targets Cancer Antibody
Compugen Announces Gpcr Ligand Discovery License Option Agreement Compugen Announces Vivo Confirmation Cardiovascular Therapeutic Potential Novel
Compugen Appoints Anat Cohen-dayag Martin Gerstel Co-ceos Compugen Awarded Grants Israel Office Chief Scientist
Compugen Collaborate Teva Discovery Novel Biomarkers Drug Toxicity Compugen Ltd
Compugen Ltd Employee Share Option Plan 1996 Compugen Ltd Notice Annual General Meeting Shareholders Held
Compugen Ltd Reports Year-end 2004 Financial Results Compugen Ltd Reports Year-end 2008 Financial Results
Compugen Ltd Review Full 2006 Results Tuesday 2007 Compugen Participate Diagnostics Panel Rbc Capital Markets 2006
Compugen Present Experimental Data Mcp-1 Antagonist Candidate Gtcbio`s Compugen Receives Deficiency Letter Nasdaq Respect Stockholders Equity
Compugen Reports 2005 Financial Results Compugen Reports 2006 Financial Results
Compugen Reports 2007 Financial Results Compugen Reports 2009 Financial Results
Compugen Retains Porter Novelli Life Sciences Corporate Communications Compugen Share Option Plan 1998
Compugen Share Option Plan 2000 Compugen`s Current Expectations Respect Financial Results 2005 Follows
Conditions Middle East Israel Harm Operations Conference Call Held 1000 Edt
Conference Call Held 1000 Est Conference Call Web Cast Information
Conference Call Webcast Information Consent Independent Registered Public Accounting Firm
Consulting Agreement Shomar Corporation Controlled Martin Gerstel Chairman Contact
Contacts Contingencies
Controls Procedures Convertible Loan Agreement
Critical Accounting Policies Current Validated Discovery Platforms
Current World-wide Financial Crisis Impact Capital Continue Indefinitely Data Presented Gtcbio`s Cancer Drugs Research Development Conference
Depend Significantly Collaborator Licensees Development Commercialization Therapeutic Diagnostic Depend Significantly Collaborators Licensees Development Commercialization Therapeutic Diagnostic
Dependence Licensing Collaboration Agreements Parties Presents Number Risks Deposits Marketable Securities Cont
Description Ordinary Shares Description Securities Other Equity
Development Marketing Products Based Discoveries Subject Governmental Regulation Diagnostic Activities
Diagnostics Activities Diagnostics Unit
Difficult Enforce Judgment Against Officers Directors Assert Securities Directors Options
Directors Senior Management Directors` Options
Disclosure Controls Procedures Discovery Compounds Enhancing Responsiveness Frequently Used Cancer Drugs
Discovery Engines Discovery Highlights Compugens Demand Capabilities Agreement Includes Research
Discussion Financial Statements Dividend Distributions
Dividend Liquidation Rights Dividends
Documents Display Donations
Election Directors Election Directors Terms Office
Employees Environmental Regulation
Equity Financing Estimates Existing Resources Sufficient Fund Planned Operations Approximately
European Fund Simap Consortium European Union`s Framework Program
Evogene Ltd Exchange Controls
Existence Party Intellectual Property Rights Prevent Developing Discoveries Experience Conducting Managing Human Trials Fail Such Business
Explanatory External Directors
F-8 F14
F19 Factors Related Discovery Development Activities Commercialization Discoveries
Factors Related Financial Results Financing Needs Factors Related Operations
Fasb 123r Federal Income Tax Consequences Holder Pfic Complex Consult
Financial Income Net Financial Information
Financial Results Financial Statements
Firm Report Registered Public Accounting Focus Therapeutic Peptides Antibody Drug Targets Collaborations Plans
Foreign Currency Exchange Risk Inflation Form 20-f
Form 6-k Form Placement Notice
Forward-looking Statements General
General Cont General Corporate Tax Structure
General Meetings Geneva Platform Presented Cold Spring Harbor`s Pharmacogenomics Meeting
Genomics-based Discovery Collaborations Geographic Information Major Customers Cont
Govermental Grants Governing Law Jurisdiction
Government Regulation Governmental Other Grants
Governmental Other Grants Cont Governmental Policies Materially Affected Affect Operations
Guidance Held 2007
Held 2008 Held Thursday 2009
Held Tuesday 2005 Held Tuesday 2007
Held Wednesday 2006 History Development
History Losses Expect Incur Future Never Achieve Sustain Holders Ordinary Shares Residents Required Pay Additional Federal
Holders Ordinary Shares United States Residents Required Pay Http Jpetaspetjournalsorg Cgi Content Abstract Jpet108145821v1
Impact Currency Fluctuations Impact Inflation Devaluation Dollar Against New Israeli Shekel
In-house Therapeutic Proteins Diagnostic Markers Pipeline Indemnification Insurance
Indemnification Remedies Index
Index Exhibits Information Reporting Back-up Withholding
Infringe Party Rights Become Involved Litigation Materially Harm Intellectual Property Rights
Interest Rate Risk Internal Auditor
Investment Evogene Ltd Israeli Government Research Development Grants
Israeli Taxation Investment Programs Keddem Bioscience Ltd
Key Objectives Leads Computational Biology Platform
Legal Proceedings Licensees Collaborators Unable Obtain Regulatory Approval Therapeutic Diagnostic
Limitations Rights Own Securities Limited Business Experience Resources Discovery Development Therapeutic Diagnostic
Limited Experience Resources Discovery Development Therapeutic Diagnostic Product Liquidity Capital Resources
Major Shareholders Management Annual Report Internal Control Over Financial Reporting
Material Modifications Rights Security Holders Proceeds Matters Relating 2007 Annual General Meeting
Matters Relating 2008 Annual General Meeting Matters Relating 2009 Annual General Meeting
Medarex Medarex Compugen Announce Therapeutic Antibody Co-development Agreement
Methodology Enabled Discovery Novel Therapeutic Protein Candidates Minutes
Miscellaneous Naomi Rabbie
Net Cash Provided Financing Activities Net Cash Provided Investing Activities
Net Cash Used Investing Activities Net Cash Used Operating Activities
Net Liquidity Net Research Development Expenses Expected Account Total Operating
Never Make Discoveries Suitable Development Therapeutic Diagnostic Products New Directors Elected Company`s Annual Meeting
New Indication Known Cns Drug Initially Predicted Discovery Non-plan Options
Not Able Find Additional Collaborators Licensees Agree In-license Not Able Find Collaborators Licensees Agree License Discoveries
Not Able Obtain Maintain Patent Protection Inventions Fail Not Able Obtain Maintain Patent Protection Inventions Relate
Not Able Protect Non-patented Proprietary Data Technologies Discoveries Not Continue Entitled Certain Tax Benefits
Not Continue Receive Research Development Grants Entitled Certain Not Successful Hope Implementing Evolving Business Model
Notices Novel Peptide Was Predicted Using Compugens Dac Blockers
Objects Purposes Office Chief Scientist
Officer Certificate Officer Rachel Bart General Counsel
Operational Financial Plans 2009 Ordinary Shares Delisted Nasdaq Global Market Result Liquidity
Ordinary Shares Traded Market Result Price Variations Organizational Structure
Other Accounts Payable Accrued Expenses Other Business
Other Committees Other Selected Customers
Outside Independent Directors Overview
Overview 2009 Plans Presented Healthcare Conference Today Part
Peptide Discovered Using Compugens Immunoassay Diagnostics Discovery Platform Peptide Was Predicted Using Compugens Dac Blockers Discovery
Peptides Discovered Using Compugens Gpcr Ligand Discovery Engine Peptides Initially Predicted Using Compugens Gpcr Ligand Discovery
Pharmaceutical Industry Generally Ready Consider In-licensing Potential Therapeutic Pharmaceutical Industry Reluctant In-license Potential Therapeutic Products Early
Pinchas Rosen Street Tel Aviv 69512 Israel Plans Initiate Commercialization Half 2009
Platform Further Strengthens Compugens Capabilities Peptide Therapeutics Area Platform Published Proceedings National Academy Sciences
Powers Directors Predictive Biology Based Discovery Platforms
Presented Leading International Conferences Principal Accountant Fees Services
Principal Capital Expenditures Principal Shareholders
Proceedings Board Directors Products Commercial Offerings
Projected Cash Uses Balances Property Plant Equipment
Property Plants Equipment Proposal Ratify Appointment Independent Public Accountants
Provisions Israeli Law Delay Prevent Affect Potential Acquisition Purchases Equity Securities Issuer Affiliated Purchasers
Quantitative Qualitative Disclosures Market Risk Raw Materials
Recent Developments Recent Operating Developments
Regulation Human Tissue Regulation Products Developed Governmental Support
Regulation Products Developed Support Research Development Grants Related Party Transactions
Relaxin Receptor Gpcr Compugen Novel Peptide Ligands Demonstrated Rely Access Public Commercial Databases Feed Discovery Engines
Remainder Page Intentionally Blank Remuneration Directors
Remuneration Directors Senior Management Report Foreign Private Issuer
Report Independent Registered Public Accounting Firm Auditors Representations Warranties Borrower
Required Allocate Substantial Additional Funds Future Discovery Development Required Allocate Substantial Additional Funds Future Discovery Validation
Research Development Expenses Expected Account Total Operating Research Development Grants
Research Development Patents Licenses Research Discovery Activities
Research Discovery Unit Resolved Appoint Directors Nominated Above
Results Operations Adversely Affected Devaluation Dollar Against New Results Operations Adversely Affected Inflation Currency Fluctuations
Results Operations Adversely Affected Inflation Devaluation Dollar Against Results Operations Negatively Affected Obligation Key Employees Perform
Results Relaxin Related Peptides Presented 2008 Conference Revenue Grants Recognition
Revenue Recognition Revenues
Revenues Generate Commercialization Technologies Discoveries Limited Because Israeli Revenues Generate Commercialization Technologies Discoveries Reduced Because Obligations
Revision Sfas 123 Require Record Employee Stock-based Compensation Rights Attached Ordinary Shares
Rights Signature Rubber Stamp Risk Factors
Risks Inherent Development Commercialization Therapeutic Diagnostic Products Materialize Sales Marketing Business Development
Sarbanes-oxley Act 2002 Seasonality Raw Materials
Securities Exchange Act 1934 Securities Registered Pursuant Act
Securities Reporting Obligation Pursuant Act Selected Customers Collaborators
Selected Existing Customers Collaborators Share Capital
Share Option Plans Share Ownership Directors Senior Management
Share Price Been Volatile Believe Likely Continue Share Price Been Volatile Future Limit Investors Ability
Share Price Been Volatile Future Limit Investors` Ability Share Price Decline Operating Results Fluctuate Fail Meet
Share Price Trading Volume Been Volatile Future Limit Shareholders Equity
Shareholders Equity Cont Signature
Signatures Significant Accounting Policies
Significant Accounting Policies Cont Significant Changes
Significant Investment Some Existing Shareholders Exert Control Over Not Make
Special Provisions Relating Measurement Taxable Income Special Provisions Relating Taxation Inflationary Conditions
Strategy Subject Claims Related Hazardous Chemicals Biological Materials Harm
Subject Claims Related Hazardous Chemicals Radioactive Biological Materials Subsequent Event
Subsidiaries Subsidiary
Success Business Largely Depends Ability Continue Develop Enhance Table Contents
Tables Follow Tabular Disclosure Contractual Obligations
Tax Benefits 2005 Amendment Tax Benefits Amendment Became Effective 2005
Tax Benefits Income Approved Enterprises Before 2005 Tax Benefits Law Encouragement Capital Investments 1959
Tax Benefits Law Encouragement Industry Taxes 1969 Tax Benefits Prior 2005 Amendment
Tax Benefits Research Development Tax Consequences Passive Foreign Investment
Taxation Disposition Ordinary Shares Taxation Dividends Paid Ordinary Shares
Taxes Income Taxes Income Cont
Therapeutic Activities Therapeutic Candidates
Therapeutic Candidates Now Undergoing Validation Therapeutics Activities
Therapeutics Unit Transfer Shares
Transmission Shares Trend Information
Trend Towards Consolidation Trend Towards Consolidation Pharmaceutical Biotechnology Industries Adversely Affect
Trend Towards Consolidation Pharmaceutical Diagnostic Biotechnology Industries Adversely Trend Towards Making Genomic Data Related Software Publicly
Unable Continue Successfully Apply Research Development Grants Financial Unable Hire Retain Key Personnel Sufficiently Qualified Employees
Unable Raise Additional Capital Future Need Curtail Cease Unable Recruit Successor Mor Amitai Hire Retain Other
Unable Safeguard Integrity Security Confidentiality Data Customers Other Unable Safeguard Integrity Security Confidentiality Data Parties Business
Unable Safeguard Integrity Security Confidentiality Data Parties` Business United States Federal Income Tax Consequences Non-us Holders
United States Federal Income Tax Considerations Units Formed Support Recently Announced Development Commercialization Plans
Update Financial Status Update Operations
Voting Rights Wholly-owned Subsidiary Keddem Bioscience Ltd Not Able Raise
Winding Year-end 2005 Financial Results
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki